本期信息
根据金斯瑞生物科技（股票代码：01548）公告，2025财年（截至2025年12月31日止年度）经调整净利润预计约2.07亿美元至2.42亿美元，相较上期约0.60亿美元增长246.5%至304.3%。公告显示，本期盈利能力的增长主要得益于许可收益的显著提升。公司预计本期许可收益约2.56亿美元至2.99亿美元，上期为约0.024亿美元。
业务分项
公告指出，上述许可收益的增长主要来自礼新医药科技有限公司带来的分许可收益。管理层认为，此项收入迅速扩大是推动公司整体盈利能力提升的重要动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.